sf-rvn
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 30, 2023 (NCT06101173)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- PoliovirusImmunity, active
Poliovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06577298 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2024 | Tianjin Cansino Biotechnology Inc, University of Indonesia |
| NCT06101173 | Phase 1 | Dec 30, 2023 | Novotech, Nucleus Network Ltd, Tianjin Cansino Biotechnology Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tianjin Cansino Biotechnology Inc | For profit | 2 | 2 | 2 | 2023 |
| Novotech | For profit | 1 | 0 | 1 | 2023 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2023 |
| University of Indonesia | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1